Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
暂无分享,去创建一个
R. Paredes | V. Johnson | D. Kuritzkes | R. D’Aquila | B. Schackman | C. Shikuma | H. Ribaudo | R. Gulick | S. Fiscus | W. Meyer | Francoise F. Giguel | C. Lalama
[1] Gregory S Turenchalk,et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. , 2009, The Journal of infectious diseases.
[2] S. Hammer,et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. , 2008, JAMA.
[3] Michael Monsour,et al. Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.
[4] Edward P Acosta,et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. , 2008, The Journal of infectious diseases.
[5] D. Kuritzkes,et al. Racial Differences in Virologic Failure Associated With Adherence and Quality of Life on Efavirenz-Containing Regimens for Initial HIV Therapy: Results of ACTG A5095 , 2007, Journal of acquired immune deficiency syndromes.
[6] R. Paredes,et al. Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. , 2007, Journal of virological methods.
[7] M. Kozal,et al. The Incidence of HIV Drug Resistance and Its Impact on Progression of HIV Disease Among Antiretroviral-Naïve Participants Started on Three Different Antiretroviral Therapy Strategies , 2007, HIV clinical trials.
[8] R. Paredes,et al. High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998–2004 , 2007, AIDS.
[9] D. Kuritzkes,et al. A comparison of three initial antiretroviral AIDS regimens. , 2007, The New England journal of medicine.
[10] Fangping Cai,et al. Detection of minor drug-resistant populations by parallel allele-specific sequencing , 2007, Nature Methods.
[11] M. Kozal,et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial , 2006, The Lancet.
[12] J. Mellors,et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[13] Hauke Walter,et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters , 2005, AIDS.
[14] M. Weinstein,et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] James R. Knight,et al. Genome sequencing in microfabricated high-density picolitre reactors , 2005, Nature.
[16] R. Shafer,et al. Detection of Minority Populations of HIV-1 Expressing the K103N Resistance Mutation in Patients Failing Nevirapine , 2005, Journal of acquired immune deficiency syndromes.
[17] Victor DeGruttola,et al. Clinically Validated Genotype Analysis: Guiding Principles and Statistical Concerns , 2004, Antiviral therapy.
[18] Christopher D Pilcher,et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. , 2004, The New England journal of medicine.
[19] C. Charpentier,et al. Role of Minority Populations of Human Immunodeficiency Virus Type 1 in the Evolution of Viral Resistance to Protease Inhibitors , 2004, Journal of Virology.
[20] S. Hammer,et al. Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. , 2004, The Journal of infectious diseases.
[21] V. Johnson,et al. Accuracy of the TRUGENE HIV-1 Genotyping Kit , 2003, Journal of Clinical Microbiology.
[22] F. Brun-Vézinet,et al. Predictors of the Virological Response to a Change in the Antiretroviral Treatment Regimen in HIV-1-Infected Patients Enrolled in a Randomized Trial Comparing Genotyping, Phenotyping and Standard of Care (Narval Trial, Anrs 088) , 2002, Antiviral therapy.
[23] Lidia Ruiz,et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial , 2002, AIDS.
[24] T. Merigan,et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy , 2000 .
[25] A. Wu,et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments , 2000, AIDS care.
[26] S. Hammer,et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.
[27] W E Barlow,et al. Analysis of case-cohort designs. , 1999, Journal of clinical epidemiology.
[28] P. Harrigan,et al. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. , 1999, AIDS.
[29] J. J. Henning,et al. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.
[30] T. Tanwandee,et al. Improved methods for quantification of human immunodeficiency virus type 1 RNA and hepatitis C virus RNA in blood using spin column technology and chemiluminescent assays of PCR products , 1997, Journal of medical virology.
[31] D. Richman,et al. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients , 1996, Journal of virology.
[32] D. Richman,et al. A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of > 500/mm3: AIDS Clinical Trials Group Protocol 208. , 1995, The Journal of infectious diseases.
[33] J. Corbeil,et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy , 1994, Journal of virology.
[34] Amalio Telenti,et al. Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .
[35] S. Hammer,et al. Antiretroviral Treatment of Adult HIV Infection 2008 Recommendations of the International AIDS Society–USA Panel , 2008 .
[36] S. Hammer,et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. , 2000, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[37] C. Loveday,et al. Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection , 2000 .
[38] R. Prentice,et al. Opportunities for enhancing efficiency and reducing cost in large scale disease prevention trials: a statistical perspective. , 1990, Statistics in medicine.
[39] S. Hammer,et al. Antiretroviral Drug Resistance Testing in Adult Hiv-1 Infection: 2008 Recommendations of an International Aids Society–usa Panel , 2022 .